1 Department of Health Care, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
2 Breast Thyroid Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Cancer Biother Radiopharm. 2019 Jun;34(5):297-305. doi: 10.1089/cbr.2018.2703. Epub 2019 Mar 22.
Ruyiping is an effective traditional Chinese herbal medicine formula for preventing postoperative recurrence and metastasis of breast cancer. However, the exact function and underlying mechanism of Ruyiping in breast cancer remain unclear. After breast cancer cell lines MDA-MB-231 and MDA-MB-468 were treated with Ruyiping, the CCK8, colony formation, wound-healing, and transwell invasion assays were used to examine cell proliferation, migration, and invasion, respectively. Flow cytometry was performed to examine the effect of Ruyiping on cell cycle distribution. Western blot was performed to examine the expression of related proteins, and the activity of MMP9 was detected using Gelatin zymography assay. Ruyiping treatment significantly inhibited cell proliferation and viability of MDA-MB-231 and MDA-MB-468 cells. Ruyiping was also revealed to trigger cell cycle arrest at the G2 phase in MDA-MB-231 and MDA-MB-468 cells. Moreover, Ruyiping suppressed the migration and invasion abilities of MDA-MB-231 and MDA-MB-468 cells . Furthermore, Ruyiping blocked the activity of MMP9 in MDA-MB-231 and MDA-MB-468 cells. Additionally, western blotting showed that Ruyiping attenuated epithelial-to-mesenchymal transition (EMT) of breast cancer through downregulation of N-cadherin, Vimentin, Snail1, and Snail2 and upregulation of E-cadherin. The authors observed that the components of Ruyiping Pseudobulbus Cremastra seu pleiones polysaccharide and curcumol showed significant suppression in the growth and invasion of breast cancer cell. The observations of this study suggest the antitumor properties of Ruyiping in cell growth and invasion of breast cancer, which are modulated by induction of cell cycle arrest and reduction of MMP9 and EMT.
如医平是一种预防乳腺癌术后复发和转移的有效中药方剂。然而,如医平在乳腺癌中的确切作用和机制尚不清楚。
用如医平处理乳腺癌细胞系 MDA-MB-231 和 MDA-MB-468 后,分别用 CCK8、集落形成、划痕愈合和 Transwell 侵袭实验检测细胞增殖、迁移和侵袭,流式细胞术检测细胞周期分布的影响。Western blot 检测相关蛋白的表达,明胶酶谱法检测 MMP9 的活性。
如医平处理显著抑制 MDA-MB-231 和 MDA-MB-468 细胞的增殖和活力。如医平还导致 MDA-MB-231 和 MDA-MB-468 细胞的细胞周期阻滞在 G2 期。此外,如医平抑制 MDA-MB-231 和 MDA-MB-468 细胞的迁移和侵袭能力。此外,如医平阻断了 MDA-MB-231 和 MDA-MB-468 细胞中 MMP9 的活性。此外,Western blot 显示如医平通过下调上皮间质转化(EMT)标志物 N-钙黏蛋白、波形蛋白、Snail1 和 Snail2 以及上调 E-钙黏蛋白来抑制 EMT。作者观察到如医平假鳞茎莪术多糖和莪术醇的成分对乳腺癌细胞的生长和侵袭有显著抑制作用。
本研究观察到如医平在乳腺癌细胞生长和侵袭中具有抗肿瘤作用,其作用机制是通过诱导细胞周期停滞、降低 MMP9 和 EMT 来实现的。